Warnex Inc.

Warnex Inc.

September 09, 2005 08:56 ET

Warnex reports on injunction affecting supplier

LAVAL, QC, Sept. 9 - Warnex Inc. (TSX:WNX) announced today that it
has been advised that Bio-Rad Laboratories and MJ Research have suspended the
production and the sale of MJ Research PCR thermal cyclers in the United
States. Currently, the Warnex™ Rapid Pathogen Detection System incorporates
the MJ Research PCR thermal cyclers in its platform for performing proprietary
pathogen detection tests.

This suspension follows a U.S. Court injunction obtained by Applera
Corporation, the parent of Applied Biosystems (ABI), against Bio-Rad
Laboratories and MJ Research. Bio-Rad has responded to Applied Biosystem's
announcement of this injunction by stating "that it is dismayed" since it
"believes that it and ABI had reached a settlement of the litigation and this
fact has been communicated to the Court by both parties."

"As we have adequate PCR equipment in stock to cover anticipated sales in
the near future, we will continue to execute our marketing and sales strategy
as planned without interruption," said Mark Busgang, President and CEO. "We
have already identified alternative PCR suppliers whose products can be
seamlessly adopted to our pathogen detection system."

About Warnex

Warnex (www.warnex.ca) is a publicly traded (TSX: WNX) Canadian
biotechnology company devoted to protecting public health by providing
advanced diagnostic and quality control products and services to the
pharmaceutical, agri-food, and healthcare sectors. Warnex's genomics-based
technology offers a versatile detection platform that produces accurate
results rapidly, using Real-Time PCR technology combined with unique genetic
markers and software. Applications range from pathogen detection in foods and
GMO testing to farm-to-fork traceability using Molecular Bar Codes. Our
development pipeline includes applications in the detection of viruses,
toxins, yeasts, and fungi, as well as meat speciation and bioterrorism.
Warnex's profitable and growing analytical, bioanalytical, and clinical
service groups offer a variety of quality control services, method development
and validation, contract R&D, bioavailability and bioequivalence studies for
clinical trials, and medical laboratory testing.


Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, such as market
conditions, currency, technological, financial, competitive and other
important factors that could cause actual results to differ materially from
those anticipated in the forward-looking statements, please refer to Warnex's
Annual Report under the heading Risks and Uncertainties in the Management's
Discussion and Analysis section. Consequently, actual results may differ
materially from the anticipated results expressed in these forward-looking
statements. Warnex disclaims any intention or obligation to update any
forward-looking statements, whether as a result of new information or

Contact Information